Abiopharma

Withdraw - Notice Of Record Date

Withdraw - Notice Of Record Date

Withdraw - Cash Dividend/ Distribution :: Mandatory

General Announcement: ANNOUNCEMENT ON THE EVALUATION REPORT ON THE 2024 ACTION PLAN AND ON THE 2025 ACTION PLAN

FDA approve CEFAZOLIN SODIUM

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve TOPIRAMATE

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve QUINIDINE SULFATE

FDA approve TOLTERODINE TARTRATE

FDA approve NALOXONE HYDROCHLORIDE

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve FENOFIBRATE

FDA approve MEROPENEM

FDA approve MEROPENEM